Date: 2016-11-02
Type of information: Nomination
Compound:
Company: Targovax (Norway)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On November 2, 2016, Targovax announced that Gunnar Gårdemyr, the Company's Chief Executive Officer, has stepped down. The Board of Directors has appointed Oystein Soug, currently the Company's Chief Financial Officer, to the role of Chief Executive Officer, effective immediately. The Company has initiated a search for a new Chief Financial Officer.
Financial terms:
Latest news:
